Research programme: cardiovascular disease - Argenta Discovery/Teijin
Latest Information Update: 10 Nov 2006
At a glance
- Originator Argenta Discovery; Teijin Pharma
- Developer Argenta Discovery
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 10 Nov 2006 No development reported - Preclinical for Cardiovascular disorders in United Kingdom (unspecified route)
- 16 Jun 2003 Preclinical trials in Cardiovascular disorders in United Kingdom (unspecified route)